Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Kristin WendlandDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Göttingen, Germany. Kristin.Wendland@med.uni-goettingen.de.ORCID http://orcid.org/0000-0002-6844-1959
Milena IrsfeldDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Göttingen, Germany.
Kathrin SchreiberDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Göttingen, Germany.
Katharina TernkaDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Göttingen, Germany.
Christine StadelmannGerman Center for Child and Adolescent Health (DZKJ), Göttingen, Germany.
Stefan NesslerDepartment of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.
Jutta GärtnerDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Göttingen, Germany.
Matthias KettwigDepartment of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Göttingen, Germany. Matthias.Kettwig@med.uni-goettingen.de.ORCID http://orcid.org/0000-0003-4804-7716
Funding
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (Federal Ministry for Education, Science, Research and Technology) 01GL2402C, and 01GL2402Bundesministerium für Bildung, Wissenschaft und Kultur (Federal Ministry of Education, Science and Culture) 01GL2402C, and 01GL2402Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2067/1- 390729940, TRR274, Ga354/16-1
6 · The paper itself
Abstract
RNaseT2-deficient cystic leukoencephalopathy (CLE) presents with severe psychomotor retardation, cystic brain lesions, white matter alterations, and cerebral atrophy. The Rnaset2
Indexed as
Interferon Type IMicrogliaNeuroinflammatory DiseasesPyroptosisRibonucleasesAnimalsDisease Models, AnimalMiceMice, Inbred C57BLMice, KnockoutInterferon Type IRibonucleases
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Unlocking microglia pyroptosis in a model of type I interferon-driven neuroinflammation: lessons from Rnaset2 · full record | OpenQuestion